1 / 22

Session 4: Quality of life and targeted therapy

Session 4: Quality of life and targeted therapy. Panel:. Christoph Zielinski Vienna Austria lecture Jan Vermorken Antwerp Belgium Jeffrey Myers Houston Texas, USA Lisa Licitra Milano Italy Johan Wennerberg Lund Sweden moderation. Health:.

jamal
Download Presentation

Session 4: Quality of life and targeted therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Session 4:Quality of life and targeted therapy

  2. Panel: Christoph Zielinski Vienna Austrialecture Jan Vermorken Antwerp Belgium Jeffrey Myers Houston Texas, USA Lisa Licitra Milano Italy Johan Wennerberg Lund Sweden moderation

  3. Health: "Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity is a fundamental human right.” WHO, 1948

  4. Disability: "... any restriction or lack (resulting from an impairment) of ability to perform an activity in the manner or within the range considered normal for a human being." WHO 1980

  5. QoL: "Quality of life refers to patient's appraisal of and satisfaction with their current level of functioning as compared to what they perceive to be a possible ideal.” (Cella & Tulsky. Measuring quality of life today: Methodological aspects. Oncology 1990;4(5):29-38)

  6. How do we measure QoL? E. Hammerlid, thesis, 1997

  7. How do we measure H&N QoL? E. Hammerlid, thesis, 1997

  8. EORTC QLQ-C30 (version 3)

  9. EORTC QLQ-C30 (version 3)

  10. EORTC QLQ-C30 (version 3)

  11. EORTC QLQ-C30 (version 3)

  12. Whats the Quality of Life for H&N Ca Patients? Mats Nordgren, Thesis: HRQL in H&N Ca; A five-year prospective multicenter study, 2005

  13. HRQL in oral cancer survivors Mats Nordgren, Thesis: HRQL in H&N Ca; A five-year prospective multicenter study, 2005

  14. Targeted therapy – Therapeutic strategies Signal transduction pathways EGFR Antiangiogenesis VEGF Unique metabolic requirements Iodine 131 Hypoxic cell sensitizers

  15. Promises for the future! Targeted therapy! Advertisment, EJC 2006;42

  16. Depicting a bright future … Advertisment, Acta Oncologica 2005; 44

  17. What’s the base of evidence?

  18. Questions to consider: - Which are the common types of toxicity induced through „targeted“ treatment? - Can we reduce chemotherapeutic dosage – and thereby toxicity - by adding targeted drugs to the treatment regimen?

  19. Issues to discuss (1): - The learning curve to handle toxicities - The relationship of QoL and survival in targeted therapy - Which evidence level (1-8) has the data collection?

  20. Issues to discuss (2): • - May QoL (QLQ C-30; H&N35) serve as an outcome end point? • Can we anticipate new toxicities? • - QoL v.s. cost/benefit of targeted therapy.

  21. What can we expect to achieve? Advertisment, EJC 2006;42

  22. ”Is our enthusiasm adequate?”

More Related